bullish
Kintor Pharma (开拓药业) Pre-IPO: Post Hearing Updates and Efficacy of Reference Products
332 Views03 May 2020 15:07
Kintor was founded by Chinese academic researchers returning from overseas. It has two main drugs, proxalutamide which targets prostate cancer and...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Kintor Pharma (开拓药业) Placement - Still Riding the COVID Momentum26 May 2021
- Kintor Pharma (开拓药业) IPO Trading: Limited Upside Despite Retail Chasing21 May 2020
- Kintor Pharma (开拓药业) IPO: Weak in Cornerstone but Still Expect Upside12 May 2020
- Kintor Pharma (开拓药业) Pre-IPO: Thoughts on Valuation25 Mar 2020
- Kintor Pharma (开拓药业) Pre-IPO: Interesting Prostate Cancer Drug but Low in Core Assets03 Mar 2020
x